Cargando…
Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia
BACKGROUND: Therapeutic vaccines can be designed to enhance existing T cell memory populations for increased protection against re-infection. In the case of herpes simplex virus type 1, recurrent disease results from reactivation of latent virus in sensory ganglia, which is controlled in part by a g...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070622/ https://www.ncbi.nlm.nih.gov/pubmed/21429183 http://dx.doi.org/10.1186/2042-4280-2-5 |
_version_ | 1782201393742872576 |
---|---|
author | Himmelein, Susanne St Leger, Anthony J Knickelbein, Jared E Rowe, Alexander Freeman, Michael L Hendricks, Robert L |
author_facet | Himmelein, Susanne St Leger, Anthony J Knickelbein, Jared E Rowe, Alexander Freeman, Michael L Hendricks, Robert L |
author_sort | Himmelein, Susanne |
collection | PubMed |
description | BACKGROUND: Therapeutic vaccines can be designed to enhance existing T cell memory populations for increased protection against re-infection. In the case of herpes simplex virus type 1, recurrent disease results from reactivation of latent virus in sensory ganglia, which is controlled in part by a ganglia-resident HSV-specific memory CD8(+ )T cell population. Thus, an important goal of a therapeutic HSV-1 vaccine would be to enhance this population. METHODS: HSV-1-infected mice were treated with TAK-779 to block CCR5- and CXCR3-mediated CD8(+ )T cell migration during both acute and latent infections. Additionally, HSV-1-specific CD8(+ )T cells were transferred into HSV-1 latently infected mice to mimic the effect of a therapeutic vaccine, and their migration into trigeminal ganglia (TG) was traced during steady-state latency, or during recovery of the TG-resident memory CD8(+ )T cell population following stress-, and corticosterone-induced depletion and HSV-1 reactivation from latency. Bromodeoxy uridine (BrdU) incorporation measured cell proliferation in vivo. RESULTS: TAK-779 treatment during acute HSV-1 infection reduced the number of infiltrating CD8(+ )T cells but did not alter the number of viral genome copies. TAK-779 treatment during HSV latency did not affect the size of the TG-resident memory CD8(+ )T cell population. Transferred HSV-specific CD8(+ )T cells failed to access latently infected TG during steady-state latency, or during recovery of the TG resident HSV-specific CD8(+ )T cell population following exposure of latently infected mice to stress and corticosterone. Recovery of the HSV-specific CD8(+ )T cell population after stress and corticosterone treatment occurred with homeostatic levels of cell division and did not require CD4(+ )T cell help. CONCLUSIONS: Our findings are consistent with the notion that the CD8(+ )T cells in latently infected TG are a tissue-resident memory (Trm) population that is maintained without replenishment from the periphery, and that when this population is disrupted, it recovers without proliferation or detectable recruitment of HSV-specific CD8(+ )T cells from the blood. The compartmentalization of the HSV-specific CD8(+ )memory T cell population in latently infected TG will complicate the design of therapeutic vaccines. |
format | Text |
id | pubmed-3070622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30706222011-04-05 Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia Himmelein, Susanne St Leger, Anthony J Knickelbein, Jared E Rowe, Alexander Freeman, Michael L Hendricks, Robert L Herpesviridae Research BACKGROUND: Therapeutic vaccines can be designed to enhance existing T cell memory populations for increased protection against re-infection. In the case of herpes simplex virus type 1, recurrent disease results from reactivation of latent virus in sensory ganglia, which is controlled in part by a ganglia-resident HSV-specific memory CD8(+ )T cell population. Thus, an important goal of a therapeutic HSV-1 vaccine would be to enhance this population. METHODS: HSV-1-infected mice were treated with TAK-779 to block CCR5- and CXCR3-mediated CD8(+ )T cell migration during both acute and latent infections. Additionally, HSV-1-specific CD8(+ )T cells were transferred into HSV-1 latently infected mice to mimic the effect of a therapeutic vaccine, and their migration into trigeminal ganglia (TG) was traced during steady-state latency, or during recovery of the TG-resident memory CD8(+ )T cell population following stress-, and corticosterone-induced depletion and HSV-1 reactivation from latency. Bromodeoxy uridine (BrdU) incorporation measured cell proliferation in vivo. RESULTS: TAK-779 treatment during acute HSV-1 infection reduced the number of infiltrating CD8(+ )T cells but did not alter the number of viral genome copies. TAK-779 treatment during HSV latency did not affect the size of the TG-resident memory CD8(+ )T cell population. Transferred HSV-specific CD8(+ )T cells failed to access latently infected TG during steady-state latency, or during recovery of the TG resident HSV-specific CD8(+ )T cell population following exposure of latently infected mice to stress and corticosterone. Recovery of the HSV-specific CD8(+ )T cell population after stress and corticosterone treatment occurred with homeostatic levels of cell division and did not require CD4(+ )T cell help. CONCLUSIONS: Our findings are consistent with the notion that the CD8(+ )T cells in latently infected TG are a tissue-resident memory (Trm) population that is maintained without replenishment from the periphery, and that when this population is disrupted, it recovers without proliferation or detectable recruitment of HSV-specific CD8(+ )T cells from the blood. The compartmentalization of the HSV-specific CD8(+ )memory T cell population in latently infected TG will complicate the design of therapeutic vaccines. BioMed Central 2011-03-15 /pmc/articles/PMC3070622/ /pubmed/21429183 http://dx.doi.org/10.1186/2042-4280-2-5 Text en Copyright ©2011 Himmelein et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Himmelein, Susanne St Leger, Anthony J Knickelbein, Jared E Rowe, Alexander Freeman, Michael L Hendricks, Robert L Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title | Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title_full | Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title_fullStr | Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title_full_unstemmed | Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title_short | Circulating herpes simplex type 1 (HSV-1)-specific CD8(+ )T cells do not access HSV-1 latently infected trigeminal ganglia |
title_sort | circulating herpes simplex type 1 (hsv-1)-specific cd8(+ )t cells do not access hsv-1 latently infected trigeminal ganglia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070622/ https://www.ncbi.nlm.nih.gov/pubmed/21429183 http://dx.doi.org/10.1186/2042-4280-2-5 |
work_keys_str_mv | AT himmeleinsusanne circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia AT stlegeranthonyj circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia AT knickelbeinjarede circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia AT rowealexander circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia AT freemanmichaell circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia AT hendricksrobertl circulatingherpessimplextype1hsv1specificcd8tcellsdonotaccesshsv1latentlyinfectedtrigeminalganglia |